Literature DB >> 1832287

Atrial natriuretic factor inhibits metoclopramide stimulated aldosterone release in man.

C C Lang1, A R Rahman, A D Struthers.   

Abstract

1. Atrial natriuretic factor (ANF) has an inhibitory effect on angiotensin II and ACTH stimulated aldosterone secretion in man. The selectivity of this aldosterone suppressing effect of ANF is unclear in man. The present study investigated the effect of ANF on the increase in plasma aldosterone due to metoclopramide in man. 2. Eight normal male volunteers were studied on three occasions. Metoclopramide (10 mg slow i.v.) was given on all study days and each volunteer was randomised to receive 45 min infusion of either 5% D-glucose (placebo) or ANF (99-126) 3 or 15 pmol kg-1 min-1. 3. Metoclopramide increased plasma aldosterone to approximately 170% of baseline levels (P less than 0.01). Concomitant infusion of ANF 3 pmol kg-1 min-1 and 15 pmol kg-1 min-1 significantly attenuated this rise in plasma aldosterone to approximately 130% (P less than 0.05) and 110% (P less than 0.01) of baseline values respectively. 4. It is suggested, in the light of previous findings, that the inhibitory effect of ANF represents a non-selective action of ANF on aldosterone release.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832287      PMCID: PMC1368492          DOI: 10.1111/j.1365-2125.1991.tb05612.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Effect of atrial peptides on aldosterone production.

Authors:  K Atarashi; P J Mulrow; R Franco-Saenz
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

2.  Further evidence for a hypothalamic site of action of atrial natriuretic factor: inhibition of prolactin secretion in the conscious rat.

Authors:  W K Samson; R Bianchi
Journal:  Can J Physiol Pharmacol       Date:  1988-03       Impact factor: 2.273

Review 3.  Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis.

Authors:  J H Laragh
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

Review 4.  Inhibition of aldosterone synthesis by atrial natriuretic factor.

Authors:  M E Elliott; T L Goodfriend
Journal:  Fed Proc       Date:  1986-08

5.  Atrial natriuretic factor inhibits ACTH stimulated aldosterone, but not cortisol, secretion in man.

Authors:  J McMurray; W J Coutie; L McFarlane; A D Struthers
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  The increase of cGMP by atrial natriuretic factor correlates with the distribution of particulate guanylate cyclase.

Authors:  J Tremblay; R Gerzer; P Vinay; S C Pang; R Béliveau; P Hamet
Journal:  FEBS Lett       Date:  1985-02-11       Impact factor: 4.124

7.  Tonic dopaminergic suppression of plasma aldosterone.

Authors:  R H Noth; R W McCallum; C Contino; J Havelick
Journal:  J Clin Endocrinol Metab       Date:  1980-07       Impact factor: 5.958

8.  The role of cyclic nucleotides in atrial natriuretic peptide-mediated inhibition of aldosterone secretion.

Authors:  P Q Barrett; C M Isales
Journal:  Endocrinology       Date:  1988-03       Impact factor: 4.736

9.  Effect of atrial natriuretic peptide on ACTH, dibutyryl cAMP, angiotensin II and potassium-stimulated aldosterone secretion by rat adrenal glomerulosa cells.

Authors:  R J Schiebinger; D C Kem; R D Brown
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

10.  Atrial natriuretic peptide directly inhibits corticosteroid biosynthesis in human aldosterone-producing adenoma.

Authors:  E Gláz; K Rácz; I Varga; R Kiss; O Sergev; L Fútó; A Szécsény; Z Schaff
Journal:  Acta Med Hung       Date:  1988
View more
  1 in total

1.  Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome.

Authors:  Qi Fu; Tiffany B Vangundy; Shigeki Shibata; Richard J Auchus; Gordon H Williams; Benjamin D Levine
Journal:  Hypertension       Date:  2011-06-20       Impact factor: 10.190

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.